Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass

C. Gennari, S. Adami, D. Agnusdei, L. Bufalino, R. Cervetti, G. Crepaldi, C. Di Marco, O. Di Munno, L. Fantasia, G. C. Isaia, G. F. Mazzuoli, S. Ortolani, M. Passeri, U. Serni, L. Vecchiet

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

We present the results of two multicenter, double-blind, placebo- controlled, 2-year studies to evaluate the efficacy and tolerability of ipriflavone in postmenopausal women (PMW) with low bone mass. 453 PMW (aged 50-65 years) with a vertebral (VMD) or radial (RMD) mineral density value 1 SD lower compared with agematched controls, were randomly selected to receive oral ipriflavone (200 mg T.I.D. at meals) or matching placebo, plus 1 g oral calcium daily. Vertebral (study A, by dual X-ray absorptiometry-DXA) and radial (study B, by dual photon absorptiometry-DPA) bone density, serum bone Gla-protein (BGP), and urinary hydroxyproline/creatinine (HOP/Cr) were measured every 6 months. In both studies, the Valid Completers (VC) analysis showed a maintenance of bone mass in ipriflavone-treated women, whereas in the placebo group, bone mineral density (BMD) was significantly decreased. The final outcome was a bone-sparing effect of 1.6% in study A, and of 3.5% in study B after 2 years. The Intention to Treat (ITT) analysis confirmed the decrease in the placebo group, with no changes in ipriflavone-treated women. A significant (P <0.05) between treatment difference was found in both studies. Biochemical markers of bone turnover decreased in patients treated with ipriflavone, thus suggesting a reduction of bone turnover rate. Twenty- six women treated with ipriflavone and 28 receiving the placebo dropped out because of side effects, mainly gastrointestinal. The compliance to the oral longterm treatment was good. The results of these studies show that ipriflavone is able to prevent both axial and peripheral bone loss in PMW with low bone mass, and is well tolerated.

Original languageEnglish
JournalCalcified Tissue International
Volume61
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 1997

Fingerprint

Bone and Bones
Placebos
Bone Remodeling
Photon Absorptiometry
Bone Density
Therapeutics
Postmenopausal Osteoporosis
Intention to Treat Analysis
Hydroxyproline
Osteocalcin
ipriflavone
Minerals
Meals
Blood Proteins
Creatinine
Biomarkers
Maintenance
Calcium

Keywords

  • Bone mass
  • Ipriflavone
  • Postmenopausal osteopenia

ASJC Scopus subject areas

  • Endocrinology

Cite this

Gennari, C., Adami, S., Agnusdei, D., Bufalino, L., Cervetti, R., Crepaldi, G., ... Vecchiet, L. (1997). Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. Calcified Tissue International, 61(SUPPL. 1). https://doi.org/10.1007/s002239900380

Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. / Gennari, C.; Adami, S.; Agnusdei, D.; Bufalino, L.; Cervetti, R.; Crepaldi, G.; Di Marco, C.; Di Munno, O.; Fantasia, L.; Isaia, G. C.; Mazzuoli, G. F.; Ortolani, S.; Passeri, M.; Serni, U.; Vecchiet, L.

In: Calcified Tissue International, Vol. 61, No. SUPPL. 1, 1997.

Research output: Contribution to journalArticle

Gennari, C, Adami, S, Agnusdei, D, Bufalino, L, Cervetti, R, Crepaldi, G, Di Marco, C, Di Munno, O, Fantasia, L, Isaia, GC, Mazzuoli, GF, Ortolani, S, Passeri, M, Serni, U & Vecchiet, L 1997, 'Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass', Calcified Tissue International, vol. 61, no. SUPPL. 1. https://doi.org/10.1007/s002239900380
Gennari, C. ; Adami, S. ; Agnusdei, D. ; Bufalino, L. ; Cervetti, R. ; Crepaldi, G. ; Di Marco, C. ; Di Munno, O. ; Fantasia, L. ; Isaia, G. C. ; Mazzuoli, G. F. ; Ortolani, S. ; Passeri, M. ; Serni, U. ; Vecchiet, L. / Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. In: Calcified Tissue International. 1997 ; Vol. 61, No. SUPPL. 1.
@article{0655e5912d6a41a8b4bb83aa464e4d85,
title = "Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass",
abstract = "We present the results of two multicenter, double-blind, placebo- controlled, 2-year studies to evaluate the efficacy and tolerability of ipriflavone in postmenopausal women (PMW) with low bone mass. 453 PMW (aged 50-65 years) with a vertebral (VMD) or radial (RMD) mineral density value 1 SD lower compared with agematched controls, were randomly selected to receive oral ipriflavone (200 mg T.I.D. at meals) or matching placebo, plus 1 g oral calcium daily. Vertebral (study A, by dual X-ray absorptiometry-DXA) and radial (study B, by dual photon absorptiometry-DPA) bone density, serum bone Gla-protein (BGP), and urinary hydroxyproline/creatinine (HOP/Cr) were measured every 6 months. In both studies, the Valid Completers (VC) analysis showed a maintenance of bone mass in ipriflavone-treated women, whereas in the placebo group, bone mineral density (BMD) was significantly decreased. The final outcome was a bone-sparing effect of 1.6{\%} in study A, and of 3.5{\%} in study B after 2 years. The Intention to Treat (ITT) analysis confirmed the decrease in the placebo group, with no changes in ipriflavone-treated women. A significant (P <0.05) between treatment difference was found in both studies. Biochemical markers of bone turnover decreased in patients treated with ipriflavone, thus suggesting a reduction of bone turnover rate. Twenty- six women treated with ipriflavone and 28 receiving the placebo dropped out because of side effects, mainly gastrointestinal. The compliance to the oral longterm treatment was good. The results of these studies show that ipriflavone is able to prevent both axial and peripheral bone loss in PMW with low bone mass, and is well tolerated.",
keywords = "Bone mass, Ipriflavone, Postmenopausal osteopenia",
author = "C. Gennari and S. Adami and D. Agnusdei and L. Bufalino and R. Cervetti and G. Crepaldi and {Di Marco}, C. and {Di Munno}, O. and L. Fantasia and Isaia, {G. C.} and Mazzuoli, {G. F.} and S. Ortolani and M. Passeri and U. Serni and L. Vecchiet",
year = "1997",
doi = "10.1007/s002239900380",
language = "English",
volume = "61",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass

AU - Gennari, C.

AU - Adami, S.

AU - Agnusdei, D.

AU - Bufalino, L.

AU - Cervetti, R.

AU - Crepaldi, G.

AU - Di Marco, C.

AU - Di Munno, O.

AU - Fantasia, L.

AU - Isaia, G. C.

AU - Mazzuoli, G. F.

AU - Ortolani, S.

AU - Passeri, M.

AU - Serni, U.

AU - Vecchiet, L.

PY - 1997

Y1 - 1997

N2 - We present the results of two multicenter, double-blind, placebo- controlled, 2-year studies to evaluate the efficacy and tolerability of ipriflavone in postmenopausal women (PMW) with low bone mass. 453 PMW (aged 50-65 years) with a vertebral (VMD) or radial (RMD) mineral density value 1 SD lower compared with agematched controls, were randomly selected to receive oral ipriflavone (200 mg T.I.D. at meals) or matching placebo, plus 1 g oral calcium daily. Vertebral (study A, by dual X-ray absorptiometry-DXA) and radial (study B, by dual photon absorptiometry-DPA) bone density, serum bone Gla-protein (BGP), and urinary hydroxyproline/creatinine (HOP/Cr) were measured every 6 months. In both studies, the Valid Completers (VC) analysis showed a maintenance of bone mass in ipriflavone-treated women, whereas in the placebo group, bone mineral density (BMD) was significantly decreased. The final outcome was a bone-sparing effect of 1.6% in study A, and of 3.5% in study B after 2 years. The Intention to Treat (ITT) analysis confirmed the decrease in the placebo group, with no changes in ipriflavone-treated women. A significant (P <0.05) between treatment difference was found in both studies. Biochemical markers of bone turnover decreased in patients treated with ipriflavone, thus suggesting a reduction of bone turnover rate. Twenty- six women treated with ipriflavone and 28 receiving the placebo dropped out because of side effects, mainly gastrointestinal. The compliance to the oral longterm treatment was good. The results of these studies show that ipriflavone is able to prevent both axial and peripheral bone loss in PMW with low bone mass, and is well tolerated.

AB - We present the results of two multicenter, double-blind, placebo- controlled, 2-year studies to evaluate the efficacy and tolerability of ipriflavone in postmenopausal women (PMW) with low bone mass. 453 PMW (aged 50-65 years) with a vertebral (VMD) or radial (RMD) mineral density value 1 SD lower compared with agematched controls, were randomly selected to receive oral ipriflavone (200 mg T.I.D. at meals) or matching placebo, plus 1 g oral calcium daily. Vertebral (study A, by dual X-ray absorptiometry-DXA) and radial (study B, by dual photon absorptiometry-DPA) bone density, serum bone Gla-protein (BGP), and urinary hydroxyproline/creatinine (HOP/Cr) were measured every 6 months. In both studies, the Valid Completers (VC) analysis showed a maintenance of bone mass in ipriflavone-treated women, whereas in the placebo group, bone mineral density (BMD) was significantly decreased. The final outcome was a bone-sparing effect of 1.6% in study A, and of 3.5% in study B after 2 years. The Intention to Treat (ITT) analysis confirmed the decrease in the placebo group, with no changes in ipriflavone-treated women. A significant (P <0.05) between treatment difference was found in both studies. Biochemical markers of bone turnover decreased in patients treated with ipriflavone, thus suggesting a reduction of bone turnover rate. Twenty- six women treated with ipriflavone and 28 receiving the placebo dropped out because of side effects, mainly gastrointestinal. The compliance to the oral longterm treatment was good. The results of these studies show that ipriflavone is able to prevent both axial and peripheral bone loss in PMW with low bone mass, and is well tolerated.

KW - Bone mass

KW - Ipriflavone

KW - Postmenopausal osteopenia

UR - http://www.scopus.com/inward/record.url?scp=0030791462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030791462&partnerID=8YFLogxK

U2 - 10.1007/s002239900380

DO - 10.1007/s002239900380

M3 - Article

C2 - 9263612

AN - SCOPUS:0030791462

VL - 61

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - SUPPL. 1

ER -